The present invention pertains to quantum-scale biocidal particles and chemical reactions that disrupt and eviscerate microbial matter by combining aqueous and dry components. As halo-fullerene activation requires volatile excitation to mix, contact and collide so as to rupture microbial matter, atomic scale chemical reactions impart the requisite movement of engineered halo-fullerenes to destroy bacterial, fungal and viral matter upon contact. The present invention includes two primary mechanisms: an excitation chemistry and biocidal, hydrophobic halo-fullerenes. Upon aqueous exposure, the dry composition initiates a chemical reaction that activates biocidal halo-fullerenes to disrupt biologic surfaces in topical applications. The object of the present invention is a shelf stable, pre-packaged wiping material or dry packet for rehydration with broad spectrum antimicrobial activity. In one example, a matrix or wipe material would be comprised of densely packed and highly concentrated halo-fullerenes and a chemical reaction stimulant. When activated upon aqueous exposure, it would relax water molecules, alter hydrogen binding, and disrupt adhesion and cohesion forces that characterize surface tensions. These dynamics would then isolate sebaceous substances and free oxygen radicals, along with outgassing of carbon dioxide. The chemical reaction stimulant thus transfers energy and hyperactivates otherwise inert halo-fullerenes to form a biocidal composition. Broader utilities range from topical cleansing for personal hygiene, as well as various clinical and surgical procedures, as surgical and prophylactic lavage and rinse solutions, and enteral formulations as a hypertonic renal flush combined with short-acting diuresis. The halo-fullerene and hypertonic renal flush would cause osmotic cellular outflow, mitigate cellular microbial uptake and initial seroconversion and bloodborne events, while a botanical diuretic agent would facilitate systemic prophylaxis or treatment of UTIs.

Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one E.sub.h-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.

Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one E.sub.h-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.

Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one E.sub.h-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.

The present invention provides a pharmaceutical composition comprising a mushroom, a rhizome, a fruit, a leaf, a flower, an alga, an energy-rich liquid, a salt-rich liquid, an assist agent and an anti-oxide agent. Said pharmaceutical composition has ability to protect liver, improve autoimmunity, reduce pain caused by cancer, protect an organ from the side-effects caused by chemical cancer drugs and increase the functions of chemical cancer drugs.

The present invention provides a pharmaceutical composition comprising a mushroom, a rhizome, a fruit, a leaf, a flower, an alga, an energy-rich liquid, a salt-rich liquid, an assist agent and an anti-oxide agent. Said pharmaceutical composition has ability to protect liver, improve autoimmunity, reduce pain caused by cancer, protect an organ from the side-effects caused by chemical cancer drugs and increase the functions of chemical cancer drugs.

The present invention in various aspects and embodiments provides methods and formulations for treating inflammatory conditions of the skin and/or conditions involving compromised skin barrier function. Such diseases include blistering diseases of the skin, hereditary defects in skin barrier function, hyperproliferative conditions involving the skin, conditions associated with aging or damaged skin, immunological disorders involving the skin, among others.

The present invention in various aspects and embodiments provides methods and formulations for treating inflammatory conditions of the skin and/or conditions involving compromised skin barrier function. Such diseases include blistering diseases of the skin, hereditary defects in skin barrier function, hyperproliferative conditions involving the skin, conditions associated with aging or damaged skin, immunological disorders involving the skin, among others.

The present invention in various aspects and embodiments provides methods and formulations for treating inflammatory conditions of the skin and/or conditions involving compromised skin barrier function. Such diseases include blistering diseases of the skin, hereditary defects in skin barrier function, hyperproliferative conditions involving the skin, conditions associated with aging or damaged skin, immunological disorders involving the skin, among others.

The present invention describes a pharmaceutical preparation for use in the treatment of systemic inflammatory response syndrome (SIRS).